188 related articles for article (PubMed ID: 22875653)
1. Semaphorin 3A - a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus.
Vadasz Z; Toubi E
Lupus; 2012 Oct; 21(12):1266-70. PubMed ID: 22875653
[TBL] [Abstract][Full Text] [Related]
2. A regulatory role for CD72 expression on B cells in systemic lupus erythematosus.
Vadasz Z; Haj T; Balbir A; Peri R; Rosner I; Slobodin G; Kessel A; Toubi E
Semin Arthritis Rheum; 2014 Jun; 43(6):767-71. PubMed ID: 24461079
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus.
Vadasz Z; Haj T; Halasz K; Rosner I; Slobodin G; Attias D; Kessel A; Kessler O; Neufeld G; Toubi E
Arthritis Res Ther; 2012 Jun; 14(3):R146. PubMed ID: 22697500
[TBL] [Abstract][Full Text] [Related]
4. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis.
Catalano A
J Immunol; 2010 Nov; 185(10):6373-83. PubMed ID: 20937848
[TBL] [Abstract][Full Text] [Related]
5. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria.
Doron R; Merav L; Nasrin E; Adi SD; Elias T; Gleb S; Itzhak R; Michael R; Zahava V
Inflammation; 2022 Apr; 45(2):603-609. PubMed ID: 34562225
[TBL] [Abstract][Full Text] [Related]
6. Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus.
Wang P; Mao YM; Liu LN; Zhao CN; Li XM; Pan HF
Immunol Invest; 2020 Feb; 49(1-2):69-80. PubMed ID: 31412748
[TBL] [Abstract][Full Text] [Related]
7. [Expression and Clinical Significance of Semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus].
Gao H; Ma XX; Guo Q; Zou YD; Zhong YC; Xie LF; Shao M; Zhang XW
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(5):370-374. PubMed ID: 28219195
[No Abstract] [Full Text] [Related]
8. Semaphorin-3A,
Liu LN; Wang P; Zou YF; Xu Z; Cheng J; Zhang Y; Hu W; Pan HF
Autoimmunity; 2019 Jun; 52(4):161-167. PubMed ID: 31394943
[No Abstract] [Full Text] [Related]
9. The involvement of immune semaphorins and neuropilin-1 in lupus nephritis.
Vadasz Z; Ben-Izhak O; Bejar J; Sabo E; Kessel A; Storch S; Toubi E
Lupus; 2011 Dec; 20(14):1466-73. PubMed ID: 21951945
[TBL] [Abstract][Full Text] [Related]
10. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
Ezzat M; El-Gammasy T; Shaheen K; Shokr E
Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin 3A: an immunoregulator in systemic sclerosis.
Rimar D; Nov Y; Rosner I; Slobodin G; Rozenbaum M; Halasz K; Haj T; Jiries N; Kaly L; Boulman N; Vadasz Z
Rheumatol Int; 2015 Oct; 35(10):1625-30. PubMed ID: 25895648
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of semaphorin-3A in autoimmune diseases.
Liu LN; Li XM; Ye DQ; Pan HF
Inflammopharmacology; 2018 Jun; 26(3):655-665. PubMed ID: 29696565
[TBL] [Abstract][Full Text] [Related]
13. [Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus].
Guo Q; Ma XX; Gao H; Shi LJ; Zhong YC; Xie LF; Shao M; Zhang XW
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):892-896. PubMed ID: 33047725
[TBL] [Abstract][Full Text] [Related]
14. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
[TBL] [Abstract][Full Text] [Related]
15. Decreased serum levels of TGF-β1 are associated with renal damage in female patients with systemic lupus erythematosus.
Jin T; Almehed K; Carlsten H; Forsblad-d'Elia H
Lupus; 2012 Mar; 21(3):310-8. PubMed ID: 22072025
[TBL] [Abstract][Full Text] [Related]
16. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
Mak A; Cheung BM; Mok CC; Leung R; Lau CS
Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
[TBL] [Abstract][Full Text] [Related]
17. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
[TBL] [Abstract][Full Text] [Related]
18. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
20. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
